| Acute onset and worsening of diabetes concurrent with administration of statins. | |
| | |
MedLine Citation:
|
PMID: 16006732 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
We report a patient in whom the administration of HMG CoA reductase inhibitors (statins) might have triggered the onset and worsening of diabetes. The patient was a 48-year-old Japanese man who underwent annual medical examination but had never been told of hyperglycemia. Four months after the commencement of atorvastatin (10 mg/day) treatment, a diagnosis of diabetes mellitus was made from his typical symptoms of hyperglycemia, postprandial plasma glucose level of 29.8 mmol/l and HbA1c of 11.5%. After 2 months of insulin therapy and 3 months after the cessation of atorvastatin, almost complete resolution of diabetes was observed. During the subsequent 3 months, diet therapy alone was sufficient to control blood glucose level. Then, we prescribed pravastatin (20 mg/day). During the subsequent 3 months, HbA1c was gradually increased. However, after discontinuation of pravastatin, HbA1c was gradually decreased. In the general population, statin does not seem to have critical adverse effects on glucose tolerance, but it may uncommonly modify the natural course of the development of diabetes in certain patients. |
| | |
Authors:
|
Chie Ohmura; Hirotaka Watada; Takahisa Hirose; Yasushi Tanaka; Ryuzo Kawamori |
Publication Detail:
|
Type: Case Reports; Journal Article |
Journal Detail:
|
Title: Endocrine journal Volume: 52 ISSN: 0918-8959 ISO Abbreviation: Endocr. J. Publication Date: 2005 Jun |
Date Detail:
|
Created Date: 2005-07-11 Completed Date: 2005-10-18 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9313485 Medline TA: Endocr J Country: Japan |
Other Details:
|
Languages: eng Pagination: 369-72 Citation Subset: IM |
Affiliation:
|
Department of Medicine, Metabolism and Endocrinology, Juntendo University School of Medicine, Tokyo, Japan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Anticholesteremic Agents
/
adverse effects*,
therapeutic use Blood Glucose / drug effects, metabolism Diabetes Mellitus, Type 2 / blood, chemically induced*, therapy Hemoglobin A, Glycosylated / metabolism Heptanoic Acids / adverse effects*, therapeutic use Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects*, therapeutic use Hypercholesterolemia / blood, drug therapy* Male Middle Aged Pravastatin / adverse effects*, therapeutic use Pyrroles / adverse effects*, therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Anticholesteremic Agents; 0/Blood Glucose; 0/Hemoglobin A, Glycosylated; 0/Heptanoic Acids; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Pyrroles; 110862-48-1/atorvastatin; 81093-37-0/Pravastatin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Global fibrinolytic capacity in patients with subclinical hypothyroidism.
Next Document: Relationship between plasma hANP level and pretibial edema by pioglitazone treatment.